MacroGenics Hands Bora the Keys to Its Maryland Manufacturing Engine

MacroGenics and Bora Pharmaceuticals have entered into a definitive agreement under which Bora will acquire MacroGenics’ GMP drug substance manufacturing operations. The transaction is expected to strengthen Bora’s biologics CDMO capabilities while enabling MacroGenics to sharpen its focus on advancing its antibody-based oncology pipeline.

Under the terms of the agreement, Bora will make an upfront payment of $122.5 million before transaction-related fees and expenses. The deal is expected to close in the third quarter of 2026, subject to customary closing conditions.

As part of the transaction, Bora will assume responsibility for manufacturing operations supporting both clinical and commercial production. The transfer includes MacroGenics’ Rockville, Maryland headquarters site, which houses an FDA-approved 11,000-liter manufacturing facility, as well as a warehouse in Frederick, Maryland. Approximately 140 MacroGenics employees are expected to join Bora following completion, ensuring continuity of expertise and operations.

MacroGenics President and CEO Eric Risser said the transaction aligns with the company’s strategy to operate as a more focused organization centered on oncology innovation. He noted that the agreement provides non-dilutive capital to support pipeline development through anticipated milestones in 2026 and beyond, while maintaining access to manufacturing capabilities through a supply arrangement with Bora.

Bobby Sheng, Chairman of the Bora Group, said the acquisition supports Bora’s strategy to expand its North American biologics manufacturing presence under Bora Biologics. He emphasized that the Maryland facility and workforce will enhance Bora’s ability to deliver end-to-end biologics drug substance and drug product manufacturing services.

Following closing, MacroGenics and Bora will enter into a supply agreement under which Bora will continue to support process development and drug substance manufacturing for MacroGenics’ internal pipeline programs, ensuring seamless continuity for ongoing projects and CDMO customers.

Reference

MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals | MacroGenics, Inc.

Bora Group to Acquire MacroGenics’ GMP Manufacturing Operations for $122.5M, Securing Maryland-Based Drug-Substance Facility and Existing Commercial Orders to Scale the Group’s Integrated Technology Platform – Bora Pharmaceuticals